Investing in SomaLogic

SomaLogic, Inc. is a privately held biotechnology company with headquarters in Boulder, Colorado.

For all investment questions, please contact us.

Interested in potential investment opportunities?

SomaLogic Business News

SomaLogic Closes $121M Series A Financing Led by Casdin Capital

SomaLogic, Inc., global leader in proteomic discovery and applications transforming biomedical discovery and clinical diagnostics, announced today that the Company has successfully closed an Initial Series A capital raise of $121 Million. The Company anticipates that additional closings will occur within the next 90 days.
read more

SomaLogic Announces New Collaboration with FDA to Advance Biosimilar Development

SomaLogic, Inc. announced today an agreement with the US Food and Drug Administration (FDA)’s Division of Applied Regulatory Science to evaluate the utility of large-scale analysis of proteins (proteomics) for the identification of biomarkers that may be useful in demonstrating biosimilarity of a proposed biosimilar to a reference biologic.
read more

SomaLogic Awarded Grant from National Science Foundation Convergence Accelerator

SomaLogic, Inc. announced today that a collaborative project between SomaLogic scientists and academic researchers has received a $1 million dollar Phase 1 grant from the National Science Foundation (NSF) Convergence Accelerator program. The team will apply recent advances in quantum sensing to improve methods for proteomic screening.
read more

SomaLogic Announces New Agreement with Amgen to Accelerate Drug Discovery and Development Efforts through Comprehensive Proteomic Profiling

SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogic’s proprietary proteomics technology to help advance Amgen’s drug discovery and development programs. The agreement builds upon SomaLogic’s existing collaboration with deCODE genetics, an Amgen subsidiary based in Iceland, and will include broader application across Amgen’s pipeline.
read more

Somalogic and NEC Solution Innovators Announce Launch of Foneslife Corporation

SomaLogic, Inc. and NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, announced today the establishment of FonesLife Corporation, a new Tokyo-based company that will bring a series of new clinical health management tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese people.
read more

SomaLogic Releases New SomaSignal™ Tests for NASH and NAFLD Research

SomaLogic announced today that it has added a new set of four research use only (RUO) SomaSignal™ tests that can diagnose all four components of non-alcoholic steatohepatitis (NASH) without the need for an invasive liver biopsy.
read more

SomaScan Proteomic Technology is now Broadly Available to COVID-19 Researchers and Drug Developers to Expand and Accelerate Response to the Pandemic

SomaLogic today launched a new initiative to deploy their proteomic technology against the coronavirus pandemic. The company is making its proprietary SomaScan® Assay available to biopharma companies, academic medical investigators, and government entities working on COVID-19/SARS-CoV-2 infection under simplified terms, with data from non-pharma studies to be shared rapidly and widely.
read more

SomaLogic Adds Three New SomaSignal™ Tests to its Current Offerings

SomaLogic announced today that it has launched three additional SomaSignal™ tests to further empower individuals to manage their state of health more effectively. These new blood-based tests measure glucose tolerance, visceral fat and resting energy rate.
read more

Blood Test Beats Traditional Predictors of Multiple Disease Risks

Proteins in our blood could in future help provide a comprehensive “Liquid Health Check,” assessing our health and predicting the likelihood that we will we will develop a range of diseases, according to research published today in Nature Medicine. The study, by an international team of researchers led by scientists at SomaLogic, the University of California, San Francisco and Cambridge University in the UK, shows that large-scale measurement of proteins in a single blood test can provide important information about a wide range of health factors and can help to predict multiple disease risks.
read more

 

For all the latest SomaLogic news, please visit our News and Events page.